Why the study?
Elevated PCSK9 during cardiac ischemia/reperfusion instigates inflammatory and oxidative processes, but the effects of PCSK9 inhibitors on the heart during ischemia/reperfusion injury had not been investigated.
Does PCSK9 inhibitor administration improve cardiac function and reduce infarct size in rats with ischaemia/reperfusion injury?
Population
Male Wistar rats subjected to cardiac I/R injury (n = 10/group)
Comparison
PCSK9i (pre-ischaemia vs during ischaemia vs onset of reperfusion) vs saline control
Design
Animal experimental study
Authors
Loading...
Pre-ischaemic PCSK9i may confer experimental cardioprotection; hypothesis-generating and leaves open any clinical translation.
Does PCSK9 inhibitor administration improve cardiac function and reduce infarct size in rats with ischaemia/reperfusion injury?
Pre-ischaemic administration of a PCSK9 inhibitor provides cardioprotection against ischaemia/reperfusion injury in a rat model, suggesting benefits beyond lipid-lowering effects.
Palee et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: